David Day and a lifetime of missed moments
8 June 2018
“I couldn’t eat. Barely slept. I was the one to tell Dave it was all over. All Dave said was ‘my poor, poor babies’.” Jenny, David’s wife.
When David lost his life last year, he was 33, with three daughters under six.
David Day was one of the 20% of people with advanced melanoma have primary resistance to new drugs with ‘super progression' and we need to find out why.
The greatest challenge our clinicians currently face in treating melanoma is ‘super progression’.
Amid all our success stories, there is still a group of people with advanced melanoma for whom absolutely nothing works. About 20% of patients our medical oncologists see with advanced melanoma fall into this category.
Super progressors do not respond to existing treatments. Within a few short months, their disease progresses aggressively and relentlessly and we cannot save them.
David Day, was one such patient —a lovely young father with a wonderful family — who died last year.
The most agonising thing about patients like David is that at present, we just don’t know why they super progress.
Dr Inês Silva was part of the clinical team which treated David Day. She was studying at MIA as a Medical Oncology Fellow from Portugal. David had such a profound impact on Inês, that on completion of her Fellowship, she decided to stay on at MIA as a Research Scientist in an all-out attempt to find answers for super progressors.
Inês and the MIA research team collected blood and melanoma tissue samples from David during his treatment. They also collected similar samples from other advanced melanoma patients who have not responded to immunotherapy.
By studying the genomic profile and protein expression in each of these patients’ tumours, Ines and the MIA research team hope to understand why each drug failed to work, paving the way for new, and potentially life-saving therapies.
While there is some existing grant funding to cover her salary, a dedicated Research Scientist like Inês can’t do it alone.
We are relying on you and on the support of our donor community to collectively fund this research project including research assistants’ salaries, PhD student scholarship top-ups, equipment, and state-of-the-art research technologies such as DNA, RNA and cell sequencing. All are key to understanding and solving primary resistance and super progression.
David was a sweet, humble family man. He was a high-achiever, had forged an exceptional career as a computer engineer for Google and made a loving, happy life raising his three daughters Charlotte, 7, Emma, 5, and Annie, now 1, with his wife Jenny, his childhood sweetheart since Year 9.
Just before Christmas 2016, with Jenny heavily pregnant with little Annie, Dave found a lump under his left arm. He had Stage III melanoma. Half way through his treatment, David found another lump under his arm and a new tumour was discovered on his left hip. His melanoma had progressed to Stage IV.
In March 2017, David and Jenny were referred to Melanoma Institute Australia. He started on a clinical trial and at first, his scans looked promising.
After starting treatment, another painful melanoma appeared on David’s wrist. In the next three months, tumours sprang up in his spleen, lungs, pancreas, bones, under his skin — with up to 30 more in his liver. Even though immune cells were present, David was super progressing.
As the months passed, David suffered extreme pain, liver damage, rapid weight loss, blurred vision and internal bleeding. The clinical team switched to chemotherapy as a last resort and Annie’s christening was pushed forward.
On 25 August 2017, Jenny had the worst imaginable task of explaining to her soul mate that nothing more could be done for him.
“I was the one to tell him it was over. All he could say was “My poor, poor babies”. My heart ached. I had lost 15kg over the past five months from the stress of the whole situation. My milk dried up and I couldn’t feed Annie. It ate away at me while I put on a brave face for Dave and the kids,” says Jenny.
Jenny has very generously shared her painful story in the hope that it will help raise funds to crack the riddle of super progression.
Please give today to save someone you know from the ravages of melanoma in the future, and give them what David didn’t have- the opportunity to enjoy a lifetime of special moments with their loved ones.
World Congress on Cancers of the Skin 2018
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia welcomes new CEO Matthew Browne
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
Melanoma in Practice: Nurse Conference
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
Reducing the risk of melanoma in young adults
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia launches free e-learning education portal
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
David Day and a lifetime of missed moments
When David lost his life last year, he was 33, with three daughters under six.
Australian melanoma experts share latest breakthroughs with world's best oncologists
ASCO 2018 brings together the world's best in oncology from around the world.
ASCO 2018 – the important role of clinical trials
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
MIA Scoops Awards at the International Academy of Pathology
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Evidence drives sweeping changes to melanoma treatment recommendations
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
Melanoma and Marital Status: A Study
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
A weekend in Paris talking all things pathology...
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.
Our own 'Australian Story'
Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts.
Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.
The inspiring story of Emma Betts premieres on Australian Story
'Dear Emma' - a tribute to the life and times of a young woman determined to raise awareness about melanoma.
Toyota helps tackle Australia's national cancer - melanoma
Carole Renouf, CEO for MIA thanks Toyota for helping fuel ongoing melanoma research.
Tackling the Kokoda Trail for melanoma
Fraser Dykes tackled the Kokoda Trail on an eight day trek in memory of his friend Mark 'Bod' Boddison.
Professor Richard Scolyer presents at world's largest annual meeting of pathologists
Harvard’s Clinical Professor Martin Mihm and MIA’s Conjoint Medical Director Professor Richard Scoyler delivered a series of lectures on melanoma pathology in Vancouver, British Colombia this week at the world’s biggest annual pathology meeting.
Farewell from Carole Renouf, CEO of Melanoma Institute Australia
A message from our CEO, Carole Renouf